
ViaNautis Bio Ltd closes US$25m Series A financing
The US$25m round of cambridge-based ViaNautis Bio Ltd, founded in 2018 as SomaServe, was led 4BIO Capital, BGF (both UK), and UCB Ventures (UK, US,...

Cellectis and AstraZeneca in US$2.2bn deal
Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca...

Roche acquires Telavant Holdings to win TLA1 race
The takeover of Telavant, a 75:25 jont-venture of Roivant Sciences and the US pharmaceutical group Pfizer, however, may cost Roche up to US-$7.25bn....

Quotient Therapeutics kicks-off with US$50m financing
Flagship has confírmed to invest $50m in Quotient Therapeutics to advance development of a platform, licenced from Wellcome Sanger Institue...

Valnevas Lyme vaccine trial complets recruitment
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. announced that they have completed enrollment in the Vaccine Against Lyme for Outdoor...

Agomab Therapeutics NV raises US$100m in Series C financing
The closed financing round was led by Fidelity Management & Research Company. New investors EQT Life Sciences, Canaan and Dawn Biopharma/KKR, as...